Bullish indicating open at $55-$60, IPO prices at $37
DUBLIN—Robert Iannone, the Executive Vice President, Global Head of Research & Development, and Chief Medical (TASE:BLWV) Officer of Jazz Pharmaceuticals (NASDAQ:JAZZ), recently sold a portion of his holdings in the company. According to a recent SEC filing, Iannone sold 2,403 ordinary shares at an average price of $138.41 per share, totaling approximately $332,604.
Following this transaction, Iannone retains ownership of 79,621 shares in the company. The transaction took place on March 10, 2025, as per the filing details. Jazz Pharmaceuticals, headquartered in Dublin, operates within the pharmaceutical preparations industry, focusing on the development and commercialization of pharmaceutical products. The company maintains impressive gross profit margins of 92% and strong liquidity, with current assets more than four times its short-term obligations. InvestingPro subscribers have access to 10+ additional key insights about JAZZ’s financial health, which is rated as "GREAT" by their comprehensive scoring system.
In other recent news, Jazz Pharmaceuticals has been the focus of several analyst updates and strategic developments. The company recently announced its acquisition of Chimerix (NASDAQ:CMRX), valued at $935 million, which is expected to enhance its portfolio with the addition of dordaviprone, a promising treatment for a rare type of brain tumor. This acquisition is anticipated to be completed by the second quarter of 2025. Analysts from H.C. Wainwright have maintained a Buy rating on Jazz Pharmaceuticals, raising the stock target to $217, reflecting optimism about the acquisition’s potential financial impact.
Additionally, UBS upgraded Jazz Pharmaceuticals from Neutral to Buy, increasing the price target to $179, citing confidence in the company’s base business and its Ziihera pipeline. Truist Securities also raised its price target to $230, incorporating the potential of dordaviprone, with expectations of increased revenue forecasts for 2026. Meanwhile, RBC Capital slightly lowered its price target to $178 but maintained an Outperform rating, noting the company’s strong performance in its commercial franchises and the resilience of its drug Epidiolex.
Needham also expressed a positive outlook by lifting the stock target to $210, driven by Jazz Pharmaceuticals’ recent earnings release and strategic updates, including settlements on Epidiolex and potential extensions for Zepzelca. These developments collectively highlight Jazz Pharmaceuticals’ strategic maneuvers and analyst confidence in its future growth prospects.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.